Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Barry

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
International Journal of Clinical Oncology|November 7, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumorsSusana Campos, Ursula Matulonis, Suzanne Berlin, et al.
Annals of Surgical Oncology|August 22, 2018
Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing MastectomyAlison Laws, Kathryn Anderson, Jiani Hu, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2009
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancerDavid S Hsu, Chaitanya R Acharya, Bala S Balakumaran, et al.
JACC. Heart Failure|August 12, 2019
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab CardiotoxicityShom Goel, Jia Liu, Hao Guo, et al.
Investigational New Drugs|July 1, 2015
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney, Sally Tan, Hao Guo, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2008
A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunitiesKatherine S Garman, Chaitanya R Acharya, Elena Edelman, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2011
Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunitiesKatherine S Garman, Chaitanya R Acharya, Elena Edelman, et al.
Breast Cancer Research and Treatment|May 24, 2018
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative studyDaneng Li, Linda M McCall, Olwen M Hahn, et al.
Analytical Chemistry|January 23, 2014
Conformational ordering of biomolecules in the gas phase: nitrogen collision cross sections measured on a prototype high resolution drift tube ion mobility-mass spectrometerJody C May, Cody R Goodwin, Nichole M Lareau, et al.
Annals of Surgical Oncology|June 6, 2018
Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution SeriesSamantha Grossmith, Anvy Nguyen, Jiani Hu, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
International Journal of Clinical Oncology|November 7, 2022
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumorsSusana Campos, Ursula Matulonis, Suzanne Berlin, et al.
Annals of Surgical Oncology|August 22, 2018
Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing MastectomyAlison Laws, Kathryn Anderson, Jiani Hu, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 13, 2009
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancerDavid S Hsu, Chaitanya R Acharya, Bala S Balakumaran, et al.
JACC. Heart Failure|August 12, 2019
Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab CardiotoxicityShom Goel, Jia Liu, Hao Guo, et al.
Investigational New Drugs|July 1, 2015
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney, Sally Tan, Hao Guo, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 4, 2008
A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunitiesKatherine S Garman, Chaitanya R Acharya, Elena Edelman, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2011
Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunitiesKatherine S Garman, Chaitanya R Acharya, Elena Edelman, et al.
Breast Cancer Research and Treatment|May 24, 2018
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative studyDaneng Li, Linda M McCall, Olwen M Hahn, et al.
Analytical Chemistry|January 23, 2014
Conformational ordering of biomolecules in the gas phase: nitrogen collision cross sections measured on a prototype high resolution drift tube ion mobility-mass spectrometerJody C May, Cody R Goodwin, Nichole M Lareau, et al.
Annals of Surgical Oncology|June 6, 2018
Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution SeriesSamantha Grossmith, Anvy Nguyen, Jiani Hu, et al.
Pageof 5